No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Zhejiang Jingxin Pharmaceutical Co., Ltd. is a Chinese enterprise engaged in the full spectrum of pharmaceutical activities, from research and development to manufacturing and sales within the country. Its diverse product line includes active pharmaceutical ingredients (APIs), along with a wide array of finished medications such as antihypertensives, various antibiotics (including quinolones and cephalosporins), gastrointestinal remedies, antidiabetics, antipileptics, antihistamines, H+ pump inhibitors, H2 receptor blockers, cholesterol-lowering drugs, and antidepressants, as well as biopharmaceutical products. Additionally, the company is a provider of advanced medical display solutions, offering diagnostic, surgical, clinical, large-screen, integrated, and ultrasonic medical displays. Originally founded in 1974 as Zhejiang Jingxin Pharmaceutical Factory, the company officially rebranded to Zhejiang Jingxin Pharmaceutical Co., Ltd. in 2000 and maintains its headquarters in Xinchang, China.
www.jingxinpharm.comNo one on the platform currently holds 002020.SZ.
No tracked institution reports a position in 002020.SZ as of their last filing.
No one on the platform has traded 002020.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 13.3% | 15.0% | 13.1% | — | — | — |
| Rev. Growth % | -2.1% | 4.5% | ||||
| Profit Margin % | 18.6% | 17.3% | 15.6% | |||
| Free Cash Flow Margin % | 14.2% | 8.1% | 8.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $4.3B | -4.9% | $0.94 | $0.94–$0.94 | — | 1 |
| 2027 | $4.7B | +8.5% | $1.08 | $1.08–$1.08 | — | 1 |
| 2028 | $5.0B | +7.4% | $1.19 | $1.19–$1.19 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 3 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-26 | $0.27 | $0.23 | -14.8% |
| 2025-04-27 | $0.18 | $0.20 | +11.1% |
| 2024-10-24 | $0.19 | $0.20 | +5.3% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 002020.SZZhejiang Jingxin Pharmaceutical Co., Ltd. | $11.46 | -0.43% | $9.9B | — |
| 002019.SZYifan Pharmaceutical Co., Ltd. | $9.24 | -0.75% | $11.2B | — |
| 002022.SZShanghai Kehua Bio-engineering Co., Ltd. | $5.55 | -2.97% | $2.9B | — |
| 002030.SZDaan Gene Co., Ltd. | $5.21 | -2.62% | $7.3B | — |
| 002038.SZBeijing SL Pharmaceutical Co., Ltd. |
| $5.57 |
| -1.94% |
| $5.7B |
| — |
| IPN.PAIpsen S.A. | $160.30 | +0.75% | $13.2B | — |
| MLC.IRMalin Corporation plc | $7.00 | +0.00% | $30M | — |
Source: Financial Modeling Prep · peers by sector/industry